Cassava Sciences | PTIE - Koszty Operacyjne





Koszty Operacyjne Zmiana Data
Abbott USD 11.66B 1.2B 2026-09
Amgen USD 5.69B 6B 2026-09
Biogen USD 2.32B 663.6M 2026-09
Cara Therapeutics USD 7.05M 1.11M 2026-03
Cassava Sciences USD 9.39M 1.78M 2026-06
Eisai JPY 209.6B 6.14B 2026-06
Eli Lilly USD 10.52B 496M 2026-06
Geron USD 54.46M 15.67M 2026-09
J&J USD 18.93B 1.09B 2026-09
Merck USD 10.75B 5.02B 2026-09
Novartis USD 9.88B 325M 2026-09
Novavax USD 126.2M 23.62M 2025-12
Pfizer USD 89B 3.81B 2026-09
Roche Holding CHF 18.9B 2.12B 2026-06